Frederique Penault-Llorca explains that gene fusions are rare but present in a high number of cancers and several of them are already targetable. From an array of gene fusions, she details on NTRK family which requires a specific approach regarding detection because of an agnostic biomarker’s nature. She details about techniques for detection of alterations and the recommendations for testing algorithm to apply.

Major Sponsors

AstraZeneca Bristol-Myers Squibb MSD Servier

Main Sponsors

Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo ipsen Janssen logo Novartis Pfizer Oncology Roche